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Abstract 
 
Aims: Vascular calcification correlates with inflammation and plaque instability in a dual manner, 
depending on the spotty/granular (micro) or sheet-like/lamellated (macro) pattern of calcification. 
Modified lipoproteins trigger both inflammation and calcification via receptors for advanced 
lipoxidation/glycation endproducts (ALEs/AGEs). This study compared the roles of galectin-3 and 
receptor for AGEs (RAGE), two ALEs/AGEs-receptors with diverging effects on inflammation and 
bone metabolism, in the process of vascular calcification. 
Methods and Results: We evaluated galectin-3 and RAGE expression/localization in 62 human 
carotid plaques and its relation to calcification pattern, plaque phenotype, and markers of 
inflammation and vascular osteogenesis; and the effect of galectin-3 ablation and/or exposure to an 
ALE/AGE on vascular smooth muscle cell (VSMC) osteogenic differentiation. While RAGE co-
localized with inflammatory cells in unstable regions with microcalcification, galectin-3 was 
expressed also by VSMCs, especially in macrocalcified areas, where it co-localized with alkaline 
phosphatase. Expression of galectin-3 and osteogenic markers were higher in macrocalcified plaques, 
whereas the opposite occurred for RAGE and inflammatory markers. Galectin-3-deficient VSMCs 
exhibited defective osteogenic differentiation, as shown by altered expression of osteogenic 
transcription factors and proteins, blunted activation of pro-osteoblastogenic Wnt/β-catenin signalling 
and proliferation, enhanced apoptosis, and disorganized mineralization. These abnormalities were 
associated with RAGE up-regulation, but were only in part prevented by RAGE silencing, and were 
partially mimicked or exacerbated by treatment with an AGE/ALE. 
Conclusions: These data indicate a novel molecular mechanism by which galectin-3 and RAGE 
modulate in divergent ways, not only inflammation, but also vascular osteogenesis, by modulating 
Wnt/β-catenin signalling and independently of ALEs/AGEs. 
 
Key words: vascular calcification; inflammation; galectin-3; RAGE; Wnt/β-catenin. 
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Vascular inflammation and calcification are strictly related phenomena occurring within the vessel 
wall during atherogenesis and contributing to plaque instability. The mechanisms by which 
inflammation favors lesion progression include induction of apoptosis and necrosis of macrophages 
and vascular smooth muscle cells (VSMCs) and activation of matrix degrading processes leading to 
plaque rupture and intra-plaque hemorrhage1. In addition, inflammation may trigger vascular 
calcification via several mechanisms, including reduction of calcification inhibitors, formation of 
tissue nucleational complexes, and induction of VSMC osteogenic differentiation2. However, vascular 
calcification seems to correlate with plaque instability in a dual manner, depending on the type and 
extent of calcification3. In fact, in response to inflammatory stimuli, VSMCs produce matrix vesicles, 
where calcium precipitates to form calcification nuclei. Extension of the inflammatory process leads 
to formation of additional spotty or granular calcium deposits (microcalcification), a vicious cycle 
favoring further tissue damage and leading to plaque instability. On occasion, the process of 
calcification may switch towards formation of large plates of sheet-like, lamellated, homogeneous 
calcium deposition (macrocalcification), which is accompanied by little or no inflammation, thus 
maintaining plaque stability. 
That micro and macrocalcification differ for rate of lesion progression and severity of clinical 
outcomes has been demonstrated by an intravascular ultrasound examination. Microcalcification 
predominated in patients with acute myocardial infarction (AMI), whereas macrocalcification 
prevailed in subjects with stable angina pectoris4. A recent report has confirmed that spotty 
calcification is a marker of accelerated progression of coronary atherosclerosis5. However, the 
molecular mechanisms underlying the switch from micro to macrocalcification, i.e., from 
spotty/granular to sheet-like/lamellated calcification, and the dual mode by which calcification 
correlates with both inflammation and plaque instability have not been investigated. 
Vascular inflammation results from multiple local and systemic mechanisms, including 
modification of lipoproteins, particularly by lipoxidation and non-enzymatic glycation leading to 
formation of a heterogeneous group of compounds collectively referred to as advanced lipoxidation 
endproducts (ALEs)6 and advanced glycation endproducts (AGEs)7, respectively, which share 
biological effects6,7 and immunogenic properties8. ALE/AGE-specific epitopes found in modified 
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lipoproteins represent a prominent set of damage-associated molecular patterns, which are recognized 
by pattern recognition receptors (PRRs) of innate immunity. PRRs include the classical ALE/AGE 
receptors galectin-3 and receptor for AGEs (RAGE).  
While RAGE has been conclusively demonstrated to favour the development of atherosclerotic 
lesions by mediating the pro-inflammatory effects of AGEs/ALEs9, the role of galectin-3 in 
atherogenesis is controversial. However, the fact that galectin-3 mediates internalization and 
degradation of these by-products10 suggests an anti-inflammatory effect, consistent with our finding 
that galectin-3 deficient animals show accelerated atherogenesis on a high-fat diet11. Moreover, a role 
of RAGE in mediating vascular calcification induced by its ligands AGEs/ALEs12 and calgranulins13 
has been demonstrated both in vivo and in vitro, whereas it is unknown whether galectin-3 participates 
in this process. Interestingly, galectin-3 and RAGE have been shown to play a role in bone formation 
and resorption, respectively, thus modulating skeletal tissue homeostasis14,15.  
This study compared the roles of galectin-3 and RAGE, two ALE/AGE-binding proteins with 
opposite effects on both vascular inflammation and bone metabolism, in the process of plaque 
mineralization leading to formation of micro (spotty/granular) or macro (sheet-like/lamellated) 
calcification. Results showed that the galectin-3/RAGE dyad participates in vascular osteogenesis by 
modulating activation of pro-osteoblastogenic Wnt/β-catenin signalling, with the two receptors 
showing different plaque expression patterns and exerting diverging effects on VSMC osteogenic 
differentiation. 
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Materials and Methods 
 
See also Detailed  Methods in the online-only supplement. 
 
In vivo/ex vivo studies 
 
In these studies, we assessed the expression and localization of galectin-3 and RAGE in human 
carotid plaques and their relation with plaque phenotype (stable or unstable), type of calcification 
(spotty/granular or sheet-like/lamellated), and markers of inflammation, fibrosis, and vascular 
osteogenesis. Carotid plaques were obtained from 62 consecutive patients undergoing carotid 
endoarteriectomy (CEA) for symptomatic or asymptomatic, hemodynamically significant carotid 
stenosis (>70%). This investigation conforms with the principles outlined in the Declaration of 
Helsinki and an approval was granted by the ethical committee of the Sant’Andrea Hospital. 
Carotid sections were analyzed semiquantitatively (scores: 0=absent, 1=mild; 2=moderate; 
3=heavy) for evaluating parameters of plaque instability, inflammation, fibrosis, and calcification 
(Supplemental Table 1). Plaques were characterized according to well-defined histological criteria, 
which are associated to clinical instability16. In detail, established markers of plaque instability and 
rupture, such as hemorrhage and thrombus17, and neovascularization of the intima18 were graded. 
Then, an overall instability index for each plaque was calculated by adding the scores for hemorrhage, 
thrombosis, and intimal neovascularization. Opposite determinants of plaque vulnerability, such as 
inflammation and fibrosis, were graded separately. Plaques were also scored for the presence of 
dystrophic micro and macrocalcifications. Spotty/granular calcifications were identified as aggregates 
of granular and heterogeneous deposits of basophilic crystalline material17 with an average size of 
each granule of 0.0032±0.00021 mm2, corresponding to a circle of ∼20 µm diameter. This size is 
congruent with the definition of microcalcification found in the literature 19. Conversely, 
macrocalcifications were recognized as large plates of lamellated, homogeneous calcium deposition, 
with a sheet-like appearance17 and an average size of 1.64±1.19 mm2. Plaques were then classified as 
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microcalcified, macrocalcified or mixed, based on the presence or absence of a predominant 
calcification pattern. Finally, a total calcification score was obtained by adding the scores for 
microcalcification and macrocalcification. The presence of bone within the atherosclerotic plaque was 
scored positive when any focus of bone matrix and bone cells were both present. 
The expression of RAGE and galectin-3, the AGE/ALE Nε-carboxymethyllysine (CML)20, the 
RAGE ligand S100A1221, and the marker of osteogenic differentiation alkaline phosphatase 
liver/bone/kidney (tissue non-specific, ALPL) were evaluated immunohistochemically11,22. Cell 
distribution was evaluated by both immunoperoxidase on sequential sections and dual label 
immunofluorescence. Activity of tartrate resistant acid phosphatase (TRAP) was assessed using the 
TRAP acid phosphatase leucocyte kit (Sigma, St.Louis, MO). The gene expression of the following 
molecular markers was assessed by real-time (RT)-PCR11,22 only in plaques with a prevalent pattern 
of calcification (i.e., microcalcification or macrocalcifications/ossification): galectin-3, RAGE, 
S100A12, collagen I, the VSMC marker α-smooth muscle cell actin (α-SMA), the inflammation 
markers interferon (INF)-γ and tumor necrosis factor (TNF)-α, the osteogenic markers ALPL and 
bone gamma-carboxyglutamate (gla) protein (BGLAP), the osteogenic transcription factors Runt-
related transcription factor 2 (Runx2) and bone morphogenetic protein (BMP)-2, and the non-specific 
osteoclast marker TRAP. Results were expressed as the ratio of the target gene transcript to the 
reference gene transcript (β-actin). 
 
In vitro studies 
 
In these studies, we evaluated the effect of galectin-3 ablation and/or exposure to an ALE/AGE on 
VSMC osteogenic differentiation at 1, 2 and 3 weeks. VSMCs were isolated from aortas obtained 
from adult (aged 6 weeks) female galectin-3-deficient mice (Lgals3-/-)11,22, and the corresponding 
C57BL/6J wild type (WT) mice. Then, RAGE was silenced in WT and Lgals3-/- cells by transfecting 
them with silenced RAGE (siRAGE) expression vector and negative control or scramble according to 
the manufacturer’s protocol. Cells were grown in DMEM plus 10% fetal calf serum, supplemented 
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with either 10 mM β-glycerophosphate, 4 mM CaCl2 and 50 µg/ml ascorbic acid (osteogenic medium) 
or vehicle (normal medium)23, with or without addition of 100 µg/ml CML-modified mouse serum 
albumin (MSA), prepared as previously reported24, unmodified MSA or vehicle. Then, monolayers 
were processed for molecular and morphological analysis of osteogenic differentiation. 
Nuclear translocation of β-catenin was evaluated by Western blot, whereas mRNA expression of 
osteogenic genes and target genes of the Wnt/β-catenin pathway were assessed by RT-PCR.  VSMC 
apoptosis and proliferation/viability were also assessed. Total calcification area and number and size 
of calcification nodules were assessed morphometrically in monolayers stained with Von Kossa. To 
account for calcium deposits not detectable at light microscopy analysis, total calcium content of 
monolayers was measured using a colorimetric assay (Quantichrom Calcium Assay Kit, BioAssay 
Systems, Hayward, CA). The analysis of gene expression was performed by RT-PCR. 
 
Statistical analysis 
 
Results are expressed as mean±SD, median (interquartile range), or number of cases and 
percentage.  
Linear regression analysis was performed to assess correlation between calcification scores and 
plaque instability and inflammation indexes or galectin-3 and RAGE expression/distribution. 
The Mann-Whitney test, for continuous variables, and the Pearson chi square test, for categorical 
variables, were applied to compare clinical findings and data from micro and macrocalcified plaques. 
In the cell culture studies, differences between genotypes and treatments were assessed using the 
Student’s t test or the one-way ANOVA followed by the Student-Newman-Keuls test, for parametric 
data, and the Mann-Whitney test or the Kruskal-Wallis test, for non-parametric data. 
A P-value <0.05 was considered significant. All statistical tests were performed on raw data, using 
SPSS 10.0 statistical software. 
Results 
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In vivo/ex vivo studies 
Patients’ clinical characteristics 
See the online-only supplement and Supplemental Table 2.  
 
Histological and molecular plaques characterization 
Histological analysis revealed calcification in virtually all the plaques analyzed. Most of them 
showed a mixed pattern of calcification (26/62, 41.94%), whereas predominance of either 
microcalcification (specimens scoring 3 for micro and 0-1 for macro) or macrocalcification 
(specimens scoring 0-1 for micro and 3 for macro) was observed in 18/62 (29.03%) of the plaques. 
Moreover, 11/18 (61.1%) of macrocalcified plaques (17.2% of all plaques) showed formation of 
mature lamellar bone, in which all bone cell types and bone marrow could be identified 
(Supplemental Figure 1). 
Figure 1 shows representative images of plaques with prevalent spotty pattern of calcification 
(microcalcification), associated with inflammation and instability features, and a plaque with 
homogenous, lamellated and extended mineralization (macrocalcification), associated with fibrosis 
and a more stable phenotype. Linear regression analysis carried out in all samples showed a weak, 
though significant, correlation between the total calcification score and the overall instability index 
(R2=0.162, p<0.05); however, separate analysis showed stronger positive correlation of the instability 
index with the score for microcalcification (R2=0.711, p<0.001), and a negative one with the 
macrocalcification score (R2=0.352 p<0.001). Likewise, weak correlation, albeit statistically 
significant, was found between total calcification and inflammation scores (R2=0.127, p<0.05), with a 
clear positive (R2=0.602 p<0.001) and negative (R2=0.314, p<0.001) trend for micro- and 
macrocalcification, respectively (Supplemental Figure 2). 
RT-PCR analysis of plaques (Figure 2) revealed higher expression of INF-γ, TNF-α, and RAGE 
and slightly though statistically significantly lower levels of galectin-3 in microcalcified plaques. Also 
expression of S100A2 was higher in microcalcified plaques (not shown).  Moreover, expression of 
collagen I, ALPL and BGLAP were higher in macrocalcified plaques, whereas expression of TRAP 
was higher in microcalcified plaques. Slightly or no significant differences, respectively, were 
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observed in the expression of Runx2 and BMP-2. Immunofluorescence analysis confirmed the 
expression level of galectin-3 and RAGE in microcalcified, macrocalcified and mixed plaques 
(Supplemental Figure 3). Interestingly, symptoms of stroke or transient ischemic attack (TIA) were 
present in 3/18 subjects (16.7%) with prevailing sheet-like/lamellated calcification (macrocalcified 
plaque) and in 12/18 patients (66.7%) with prevailing spotty/granular calcification (microcalcified 
plaque) (P=0.002). No significant difference in the above parameters was found between plaques 
from non-diabetic and diabetic subjects as well as from patients with and without CKD. However, this 
finding could be due to a selection effect related to the cross-sectional design of the study, which 
included subjects with a cerebrovascular event from groups of individuals at different risk rate for that 
event as well as death. There was only a non-significant trend (75% vs. 50%) of diabetic patients to 
show mature bone formation in macrocalcified plaques, which is consistent with a previous report17 
and might be explained by the finding that diabetes increases the circulating levels of osteo-
progenitors cells25. 
 
Galectin-3 and RAGE distribution in tissue plaque 
Galectin-3 was expressed by lipid-laden cells and infiltrating inflammatory cells, but also by 
VSMCs in fibrous areas (Figure 3A-B) and, especially, in regions adjacent to sheet-like/lamellated 
calcifications (Figure 3C). In unstable, inflamed plaque regions, VSMCs expressed little, if any, 
galectin-3, whereas in fibro-calcific, non-inflamed plaque areas where macrophages are rare and 
VSMCs predominate, most VSMCs expressed galectin-3 (Supplemental Figure 4). In macrocalcified 
plaques, galectin-3 showed a pattern of positivity similar to that of the VSMC marker α-SMA and the 
marker of osteogenic differentiation ALPL (Figure 3C). Interestingly, also the subcellular distribution 
pattern of galectin-3 differed between inflammatory cells and VSMCs, since it was predominantly 
cytoplasmic and nuclear, respectively (Supplemental Figure 5). 
Instead, RAGE positivity was higher in plaques with prevalent spotty/granular calcification and 
high instability index (2.61±0.70 vs. 1.27±0.46; P<0.001), and was typically observed in regions rich 
in foam cells and/or inflammatory infiltrate co-localizing with monocytes-macrophages (Figure 3D 
and Supplemental Figure 6). The intensity and distribution of CML staining recapitulated that of 
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RAGE and also S100A12 positivity was confined to microcalcified, unstable plaques (Supplemental 
Figure 7).  
Intense enzymatic TRAP activity was shown by microcalcified, inflamed and unstable plaques, 
with clusters of inflammatory cells displaying strong positivity. In contrast, TRAP activity was low in 
macrocalcified plaques, being mainly confined to cells with an osteoclastic phenotype in ossified 
regions (Supplemental Figure 8). 
Again, no significant effect of diabetes or CKD on these parameters was detected. 
 
In vitro studies 
Molecular markers 
Osteogenic differentiation induced by osteogenic medium in Lgals3-/-- and WT-VSMCs was 
evaluated at 1, 2 and 3 weeks. RT-PCR demonstrated that the osteogenic transcription factor Runx2 
and the osteogenic marker ALPL increased over time in WT-VSMCs, whereas the VSMC marker α-
SMA decreased, as compared with cells grown in normal medium. Figure 4 shows 3-week values. 
Interestingly, galectin-3 expression was up-regulated by the osteogenic stimulus in a fashion similar 
to ALPL. RAGE and TRAP were also up-regulated, albeit to a lesser extent. However, comparing the 
absolute values, galectin-3 expression was 23 times higher than that of RAGE (not shown). More 
importantly, galectin-3 deficiency hampered the ability of VSMCs to adequately differentiate towards 
an osteogenic phenotype, as demonstrated by the blunted expression of Runx2 and ALPL, and the 
attenuated loss of α-SMA. Furthermore, galectin-3 ablation was associated with increased expression 
of RAGE in normal medium, as previously shown by our group in mesangial cells and aortic and 
renal tissues from galectin-3 deficient mice11,22, and a marked up-regulation of both RAGE and TRAP 
in osteogenic medium, as compared with WT-VSMCs. To assess whether the abnormal osteogenic 
differentiation of Lgals3-/--VSMCs was due to galectin-3 deficiency or the associated RAGE 
overexpression, RAGE was silenced in these cells. However, only Runx2 returned to values not 
significantly different from those of WT cells, whereas ALPL expression was unchanged, and TRAP 
and α-SMA mRNA levels were closer to those of Lgals3-/- than to those of WT cells. This supports 
the concept that the effect of galectin-3 deficiency was not attributable to, though it was accentuated 
 by guest on A
ugust 28, 2013
http://cardiovascres.oxfordjournals.org/
D
ow
nloaded from
 
A
cc
ep
te
d 
M
an
us
cr
ip
t
11 
by, RAGE up-regulation. To get insight into the mechanism by which galectin-3 affects osteogenic 
differentiation of VSMCs, we then investigated the Wnt/β-catenin signalling. The rationale for these 
experiments is based on the well-documented role of Wnt/β-catenin in osteoblastogenesis26 as well as 
on data showing that galectin-3 is a key regulator of this pathway through its ability to interact with 
and translocate β-catenin into the nucleus27, whereas RAGE inhibits osteoblast proliferation through 
suppression of β-catenin/Wnt signalling28. Results showed that, in WT- but not Lgals3-/--VSMCs, 
nuclear translocation of β-catenin was induced by 24-hour exposure to osteogenic medium and 
maintained at 1 week. A parallel trend was observed in the expression of the β-catenin target genes 
cyclin D1 and axin2 (the latter playing an important role in the regulation of β-catenin stability), thus 
supporting the concept that Wnt/β-catenin signalling was activated in WT but not  Lgals3-/- cells 
(Figure 5). Exposure to osteogenic medium induced apoptosis in Lgals3-/- , but not WT cells, whereas 
it increased proliferation/viability in WT, but not Lgals3-/--VSMCs (Supplemental Figure 9). 
The above data also indicate that both receptors modulate VSMC osteogenic differentiation 
independent of ALEs/AGEs. However, since these by-products up-regulate both receptors and exert 
their injurious effects through RAGE11,22,28, we then evaluated the effect of CML on the process of 
osteogenic differentiation. Molecular analysis was limited to the first two weeks (Supplemental Figure 
10), since this is the longest incubation time of VSMCs with AGEs found in the literature29 and also 
because at three weeks the mRNA expression data became irreproducible, possibly due to the 
cytotoxic effect of prolonged exposure to CML. Time course experiments in WT-VSMCs showed an 
early (one-week) pro-osteogenic effect of CML, which induced up-regulation of Runx-2, but not of 
ALPL, as compared with untreated VSMCs. Interestingly, also galectin-3 and RAGE expression was 
induced by CML treatment, whereas TRAP was not affected at this time. In contrast, at two weeks, 
while the stimulatory effect of CML on Runx-2 expression was maintained, ALPL was down-
regulated, as compared with untreated WT-VSMCs. Galectin-3 expression showed a trend towards 
normalization, whereas RAGE and TRAP showed an opposite behavior, being up-regulated by CML. 
In Lgals3-/--VSMCs, the initial pro-osteogenic effect of CML observed in WT cells was completely 
lost, since CML treatment did not modify Runx2 expression and down-regulated ALPL expression as 
compared with untreated cells, at variance with WT-VSMCs. At two weeks, CML treatment of 
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Lgals3-/--VSMCs induced marked reduction of Runx2, whereas ALPL expression remained lower 
than in untreated cells. In contrast, RAGE and TRAP and Nox1 were up-regulated vs. untreated cells. 
CML treatment of siRAGE-Lgals3-/- monolayers produced intermediate effects between those 
observed in WT and Lgals3-/--VSMCs (not shown). In response to CML, β-catenin translocation and 
Axin2 mRNA levels were reduced in WT cells, whereas nuclear β-catenin levels were unchanged and 
the expression of β-catenin target genes was further reduced in Lgals3-/--VSMCs (Figure 5). CML also 
caused an increase in apoptosis and a reduction in proliferation/viability in WT- and, to a higher 
extent, in Lgals3-/--VSMCs (Supplemental Figure 9). 
Mineralization pattern 
Morphometric analysis of monolayers stained with Von Kossa (Figure 6) revealed an altered 
mineralization process in Lgals3-/--VSMCs, with a nonsignificant reduction of total calcified area and 
a more sparse distribution of calcification nodules, which were more numerous but of smaller size 
than in WT cells. These changes were only partly affected by RAGE silencing. 
CML addition to WT-VSMCs induced a non-significant reduction of total calcified area, an 
increased number of calcifying nodules and a reduction of nodule size. Moreover, exposure to CML 
exacerbated the alteration of mineralization observed in untreated Lgals3-/--VSMCs, with further 
significant reduction of total calcified area and formation of significantly more numerous and smaller 
nodules. CML treatment also worsened mineralization of Lgals3-/--siRAGE cells. 
Interestingly, despite the differences in total calcified area reflecting differences in calcification 
pattern, total calcium contents of monolayers, as measured colourimetrically, did not differ across the 
experimental conditions (not shown). This suggests that the galectin-3/RAGE dyad affects the 
arrangement rather than the extent of mineralization, depending on both the absolute and relative 
levels of these receptors. 
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Discussion 
 
Carotid artery calcification is an unfavorable finding evidencing advanced atherosclerosis. 
However, previous reports have shown that extensive calcification could have a stabilizing influence 
on the plaque, entailing partial protection from thrombo-embolic events. In ex vivo studies, Hunt et al 
found that stroke and TIA occurred less frequently in patients who had plaques with large sheet-like 
calcifications17, and Shaalan et al showed that symptomatic plaques were less calcified and more 
inflamed than asymptomatic plaques30. Moreover, an in vivo study using multidetector computed 
tomography showed that the extent of carotid plaque calcification was inversely associated with the 
occurrence of symptoms31. 
In this study, we further support this concept by showing that sheet-like/lamellated (macro) and 
spotty/granular (micro) calcification are associated with different plaque phenotypes at both the 
molecular and morphological level. More importantly, we provide evidence that this association 
between type of calcification and plaque phenotype is related to the expression pattern of two 
AGE/ALE-binding proteins, galectin-3 and RAGE. In fact, galectin-3 was found to be expressed not 
only by inflammatory cells in unstable plaque regions, but also by VSMCs in areas of fibrosis and 
particularly of sheet-like/lamellated calcification indicating a more stable pattern. Nachtigal et al also 
reported that galectin-3 was expressed by VSMCs from CEA specimens, though it was mainly 
confined to foam cells32. In addition, we showed that, in VSMCs adjacent to extensively and 
homogenously mineralized regions from fibro-calcific plaques, galectin-3 co-localized with the 
osteogenic marker ALPL. Conversely, expression of RAGE and its ligands CML and S100A12 
prevailed in unstable, inflamed plaques with a prevalent spotty/granular calcification pattern. From an 
integrated viewpoint, the diverging relationships between galectin-3 and RAGE with sheet-
like/lamellated and spotty/granular calcification, respectively, reflect the dual mode by which vascular 
calcification correlates with both inflammation and plaque stability. We also showed that these two 
receptors display diverging effects on VSMC osteogenic differentiation. In fact, this process was 
impaired in terms of molecular changes, induction of proliferation and pattern of mineralization in 
 by guest on A
ugust 28, 2013
http://cardiovascres.oxfordjournals.org/
D
ow
nloaded from
 
A
cc
ep
te
d 
M
an
us
cr
ip
t
14 
galectin-3-deficient VSMCs, in which RAGE was up-regulated.  However, RAGE silencing restored 
only partly the osteogenic differentiation in these cells. In fact, galectin-3 was shown to exert a direct 
modulation of Wnt/β-catenin, a key event in osteogenic differentiation26. Moreover, these effects were 
independent of the AGE/ALE-binding function, though CML mimicked or aggravated the impact of 
galectin-3 ablation on VSMC differentiation through induction of RAGE expression and activation. 
Thus, accumulation of AGEs/ALEs and/or impaired galectin-3-dependent removal would favour 
dysregulation of vascular calcification mediated by the AGE-RAGE axis, leading to spotty/granular 
calcification and, hence, plaque instability.  
These findings introduce a novel molecular mechanism underlying the biological activity of the 
galectin-3/RAGE dyad in atherogenesis, i.e. these two receptors modulate the pattern of plaque 
calcification through direct and diverging actions on vascular osteogenesis, in addition to regulating 
inflammation in opposite ways. In fact, galectin-3 and RAGE showed different effects on the 
induction of differentiation markers and organization of the mineralization process in VSMCs 
exposed to osteogenic medium. Galectin-3 is needed to acquire a complete osteoblast-like phenotype 
by VSMCs, consistent with the intranuclear localization of galectin-3 and its role in β-catenin 
activation at this level. This is in keeping with the findings that, in skeletal tissue, galectin-3 is a 
downstream target of Runx2, the key regulator of osteogenic differentiation,14 and participate in the 
process of endochondral bone formation33, whereas it suppresses up-regulated osteoclastogenesis34. 
This is also consistent with the role of Wnt/β-catenin signalling in osteoblastogenesis26 and the 
regulation of this pathway by galectin-327. In contrast, RAGE appears to hamper VSMC 
osteoblatogenic differentiation and orderly calcium deposition. All together, our data point to the 
importance of galectin-3 and RAGE in determining plaque vulnerability and clinical outcomes by 
affecting both vascular osteogenesis and inflammation , which in turn triggers calcium deposition 
within the vessel wall. In plaques, RAGE could promote and perpetuate inflammation, thus favoring 
deposition of spotty/granular calcifications (microcalcifications) and hence plaque instability. 
Moreover, since RAGE was shown to be essential for osteoclast maturation and function in skeletal 
tissue both in vivo and in vitro15 and osteoclasts were hypothesized to originate from monocytes-
macrophages within the vessel wall35, it is still unclear whether RAGE affects vascular calcification 
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also by inducing osteoclast differentiation and activation. Finally, immunohistochemistry failed to 
detect VSMC RAGE expression and its variation with plaque phenotype, due to the low sensitivity of 
the technique. However, the in vitro results in cells lacking galectin-3 or exposed to CML prompt the 
speculation that, though RAGE is expressed at low levels in VSMCs, up-regulation of this receptor 
might also counteract the osteoblastogenic effect of galectin-3, possibly via inhibition of β-catenin 
activation28. This view is in keeping with the observation that, in ApoE null mice, VSMC–targeted 
expression of the RAGE ligand S100A12 resulted in an increased number of calcific nodules and 
features of plaque instability13. Conversely, galectin-3, in addition to exerting an anti-inflammatory 
action, once the calcification process has started, would drive progression of calcium deposition 
within the vessel wall towards a pattern of sheet-like/lamellated calcification (macrocalcification). 
Our data might also contribute to explain the effects of AGEs/ALEs on calcification. In fact, 
previous studies reported that VSMC osteogenic differentiation is stimulated35,36 by modified 
lipoproteins and ALEs/AGEs, at variance with osteoblast growth and function, which are 
inhibited36,37. However, we found that CML, a major RAGE ligand, did favour the initial switch of 
VSMCs towards an osteogenic phenotype, consistent with previous reports35,36, but at a later stage it 
induced a dysregulated expression of osteogenic markers associated with disorganized mineralization. 
These findings suggest that the different effects of ALEs/AGEs on vascular and bone cells are only 
apparent, actually reflecting differences in cell commitment. Thus, in vessels, ALE/AGE 
accumulation would result in disorganized tissue mineralization favouring plaque vulnerability, 
consistent with the finding that oxidized lipoproteins destabilized calcific nodules formed by 
calcifying vascular cells implanted subcutaneously in ApoE-null mice38.  
In conclusion, these results indicate that, in addition to their opposite effects on inflammation, 
galectin-3 and RAGE  regulate, in diverging ways, vascular osteogenesis, by modulating Wnt/β-
catenin signalling. They govern formation of sheet-like/lamellated and spotty/granular calcification, 
and the consequent plaque progression towards a stable or unstable phenotype, respectively. This 
represents a novel molecular mechanism underlying the activity of these ALE/AGE-receptors in the 
process of atherogenesis, even beyond their ALE/AGE-binding properties. 
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Figure legends 
 
Figure 1. Hematoxylin and eosin (H&E) and Von Kossa staining of representative serial sections of 
unstable (A and B, instability index 6 and 5, respectively) and stable (C, instability index 0) plaques. 
Atherosclerotic plaques with large lipid cores (LC), thrombosis (T) and inflammatory infiltrate (INF) 
show a spotty/granular pattern of calcification (C), as identified by aggregates of basophilic 
crystalline material in H&E-stained sections or brown-black granules in Von Kossa-stained sections. 
Plaques with no features of instability or inflammatory cells infiltration show extensive fibrosis (F) 
and large plates of sheet-like/lamellated calcification (C). 
 
Figure 2. Gene expression levels of AGE receptors, inflammation and fibrosis markers (A) and 
osteogenic markers (B) in plaques with prevalent sheet-like/lamellated (macro, white bars) or 
spotty/granular (micro, gray bars) calcification (median [interquartile range]; n=18 each group). * 
P<0.001, † P<0.01 or ‡ P< 0.05 in macro vs. microcalcified plaques. 
 
Figure 3. Immunohistochemistry for galectin-3, α-SMA, ALPL, and RAGE, and Von Kossa staining 
of representative plaques. Galectin-3 is expressed by lipid-laden cells (A, brown staining) and 
mononuclear cell infiltrates (INF) in the media and adventitia (B). In addition, also VSMCs stain for 
galectin-3, particularly in fibrous areas (F) surrounding the necrotic core (NC) (B). Moreover, intense 
galectin-3 positivity is observed near the large areas of sheet-like/lamellated calcification, with a 
staining pattern similar to that of α-SMA and ALPL (C). In contrast, RAGE positivity is negligible in 
macrocalcified plaques (D, left), whereas it is intense in microcalcified, inflamed and unstable plaques 
(D, right, same plaque as in A of Figure 2; T=thrombosis). 
 
Figure 4. Gene expression levels of Runx2, ALPL, α-SMA, galectin-3, RAGE, and TRAP in VSMCs 
from WT and Lgals3-/- mice and in Lgals3-/- cells silenced for RAGE, grown in normal medium (white 
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bars) or osteogenic medium (black bars) for 3 weeks (n = 3 in each of 3 independent experiments). * 
P<0.001 vs. normal medium; † P<0.001 vs. WT; ‡ P<0.001 vs. Lgals3-/-. 
Figure 5. Nuclear β-catenin translocation at 24 hours (A, top) and 1 weeks (A, bottom) and gene 
expression levels of cyclin D1 (B) and Axin2 (C) at 1 week in VSMCs from WT and Lgals3-/- mice 
grown in normal vs. osteogenic medium (OM) ± CML (100 µg/ml) (n=3 in each of 3 independent 
experiments). * P<0.001 vs. normal medium; † P<0.001 vs. OM; ‡ P<0.001 vs. WT. 
 
Figure 6. Von Kossa staining from representative monolayers and quantification of total calcified 
area, and calcified nodule number and size in VSMCs from WT and Lgals3-/- mice and in Lgals3-/- 
cells silenced for RAGE, grown in osteogenic medium, either untreated (white bars) or treated (black 
bars) with CML (100 µg/ml), for 3 weeks (n=3 in each of 3 independent experiments). * P<0.001 or † 
P<0.01 vs. WT cells; or ‡ P<0.01 vs. Lgals3-/- cells; § P<0.001, # P<0.01 or ¶ P<0.05 vs. untreated 
cells. 
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